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Editorial
Coronary stents and perioperative anti-platelet regimen: dilemma of bleeding and
stent thrombosis
The incidence of coronary artery disease (CAD) in the
Western population is high and increasing. Its treatment,
by coronary revascularization, was revolutionized in 1977
by Gru¨ntzig who performed the first percutaneous translu-
minal coronary balloon angioplasty in Zu¨rich, Switzerland.
Nine years later the first coronary stent was deployed
in Lausanne, Switzerland, by Sigwart and colleagues.1 2
Currently, over 90% of all percutaneous coronary interven-
tions (PCIs) involve placement of stents.3
Any PCI causes trauma to the vessel wall, rendering the
endoluminal surface thrombogenic4 and thus, adjunctive
anti-platelet medication is a crucial element in preventing
local coronary thrombosis.5 Current recommendations
call for initial dual anti-platelet therapy with aspirin and
clopidogrel.5–7 Aspirin is generally maintained for life.
Clopidogrel treatment is recommended for at least 3–
12 months depending on the type of stent implanted
(6 weeks for bare metal stents).5 7–9 There is a tendency to
maintain dual anti-platelet treatment for increasingly long
periods as it clearly improves the combined 1yr outcome
with respect to death, myocardial infarction and stroke.3
Anaesthetists thus are increasingly confronted with
patients who have had a recent stent implantation and are
on anti-platelet therapy. The key question in such patients is
whether the anti-platelet therapy should be maintained
throughout the perioperative period or stopped before
operation. There are arguments for both strategies. Patients
on aspirin and clopidogrel undergoing cardiac surgery
have an increased blood loss, require more blood transfu-
sions and have a higher incidence of re-exploration for
bleeding.10–12 Also in non-cardiac surgery, patients receiv-
ing dual anti-platelet therapy have a 25–40% increased risk
of bleeding.13–16
However, stopping anti-platelet therapy is associated with
significant morbidity and mortality. Withdrawal of aspirin in
patients with CAD is associated with a 2- to 4-fold increase
in the risk of death and myocardial infarction, even with
replacement low molecular weight heparin,17 18 compared
with patients who remain on the drug. Moreover, cessation
of anti-platelet therapy is the major independent predictor of
stent occlusion,19 20 and stent thrombosis resulting in myo-
cardial infarction after aspirin cessation has been reported
as late as 15 months after PCI with drug-eluting stents.21
Combining these data with the increased platelet adhesive-
ness and decreased fibrinolysis found in the perioperative
period, it is reasonable to hypothesize that patients who have
undergone PCI and who have recently stopped aspirin are at
a particular risk of thrombotic postoperative complications
including stent thrombosis.22
The anaesthetist faces the dilemma of stopping the anti-
platelet treatment before operation to avoid bleeding and
risking postoperative stent thrombosis, or to maintain anti-
platelet therapy perioperatively; thus risking major blood
loss but limiting the risks of postoperative stent thrombosis.
The study by Vicenzi and colleagues23 reported in this issue
of the British Journal of Anaesthesia includes an analysis
of the impact of anti-platelet agents and heparin on out-
come. The authors assessed 103 patients with coronary
stent implantation undergoing non-cardiac surgery. In all
the three participating centres institutional guidelines exis-
ted regarding the perioperative anti-platelet regimen. These
guidelines required either maintaining the anti-platelet
therapy perioperatively or stopping anti-platelet drugs for
a maximum of 3 days and replacing these drugs with
medium dose heparin coverage. The primary outcome of
this study was combined adverse outcome (cardiac, bleed-
ing, surgical, sepsis and other) during the first 3 months after
operation. The authors report a 45% complication rate and
5% mortality.23 Interestingly, all but two complications
were cardiac and most of the complications occurred early
after surgery. In keeping with earlier studies,13 24 they found
that complications are particularly frequent when surgery is
performed early (<35 days) after stent implantation. Even
though this time limit was chosen somewhat arbitrarily, the
association between very recent stenting and complica-
tions is less clear than in previous studies. In the paper of
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Vicenzi and colleagues, complications were more frequent
in patients with a recently placed coronary stent but not to
the extent that all24 or even the majority of complications
occurred in the initial 35 days.13 Somewhat surprisingly,
a multivariate analysis found that patients with and
without complications did not differ in terms of peri-
operative anti-platelet regimen. However, few details are
given with regard to the use of anti-platelet agents. The
findings of this study should be interpreted with some
caution. Patients were not randomized to one or another
heparin regimen raising the possibility of allocation bias.
No distinction is made between different types of coronary
stent. It is well established that drug-eluting stents are more
thrombogenic than bare metal stents and individual
clinicians’ knowledge of what stent was used could have
influenced management.
What do we learn from this study? Firstly, it offers further
confirmation that patients with coronary stents are at a high
risk of postoperative complications. Secondly, it supports
the use of anti-platelet agents in this population. It seems
likely that these patients are on anti-platelet drugs with good
reason. Thirdly, it suggests that bleeding in non-cardiac
surgery is not a common or important complication when
compared with the incidence of cardiac events.
We lack high level scientific evidence on the optimum
perioperative anti-platelet regimen in patients with coronary
stents. In such a situation, we would normally call for a
prospective randomized trial comparing the outcome of dif-
ferent perioperative anti-platelet regimens. Operation with
full anti-platelet therapy, stopping all anti-platelet drugs
before operation, and stopping clopidogrel but maintaining
aspirin are potential regimens. It can be argued that such a
trial would be unethical considering all the known complica-
tions of stopping the anti-platelet treatment.17–21 However,
we regularly encounter patients the evening before opera-
tion in whom all anti-platelet drugs have been stopped 7–
10 days previously by the surgeon or the primary physician.
In the guidelines of the European Society of Cardiology
for PCI,5 the authors state ‘In patients in whom prolonged
administration of clopidogrel is known to be unlikely
(i.e. major extracardiac surgery planned soon) drug-eluting
stents should be used with caution. In these patients, bare
metal stents are probably the safer choice.’ It appears that
some cardiologists expect anti-platelet therapy to be stopped
before operation anyway. Others might argue that not
stopping clopidogrel might be unacceptable considering
the increased bleeding risks10 11 14–16 and the impossibility
of using regional anaesthesia. This argument may not be
robust. The difference in packed red blood cell transfusions
in most studies is only 1–2 units,10 12 and there are several
papers describing series in which no difference was found in
terms of bleeding between patients with and without dual
anti-platelet therapy (aspirin plus clopidogrel).24 25 There
appears to be a strong case for a study in patients on
dual anti-platelet treatment who have recently undergone
PCI and now require non-cardiac surgery. This study should
compare a combined aspirin and clopidogrel therapy with
aspirin alone. Deliberately stopping all anti-platelet drugs in
such patients appears to be associated with an unacceptably
high incidence of major cardiac complications, and thus
unethical. The baseline incidence of cardiac complications
reported by Vicenzi and colleagues is so high (>40%) that,
with a hypothesized difference between groups of only 10%
as achieved in the CREDO trial,3 a preliminary sample size
analysis yielded group sizes of less than 500 patients in each
arm. Such a study thus appears realistic on a European level.
What should we do in the meantime? Without high level
scientific evidence, anaesthetists, surgeons and cardiologists
should establish local treatment algorithms for the
management of patients who have had previous PCI and
are now to undergo surgery. Such algorithms may include
the following:
 All patients should receive a thrombo-embolic prophy-
laxis with (low molecular weight) heparin. However,
heparin alone is insufficient.
 An initial period of 6–12 weeks after PCI should be
defined during which, regardless of the anti-platelet regi-
men, only life-saving operations should be performed.
 For operations that can be scheduled after this initial
period, simply stopping all anti-platelet drugs 7–10 days
before operation is unwise. The majority of patients with
coronary stents may benefit from an unchanged anti-
platelet treatment perioperatively.
 In selected patients undergoing operations, historically
associated with major blood loss or certain neurosurgical
procedures, a combined aspirin–clopidogrel treatment
might be reduced for a short period to aspirin and
(low molecular weight) heparin treatment only.
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